InterMune, Inc. (ITMN) CEO: Bittersweet Ending To A Biotech Comeback Story
8/26/2014 6:33:46 AM
InterMune Inc.’s comeback story — from a drug rejection by the FDA to an $8.3 billion buyout offer Sunday from drug giant Roche — is mixed for Dan Welch. After shedding some of the Brisbane company’s (NASDAQ: ITMN) key assets, focusing resources on a huge, new study and convincing investors to pony up more cash to support the effort, Welch and much of his leadership team may be out of jobs in a few months.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by